| scholarly article | Q13442814 |
| P2093 | author name string | Serafina Valente | |
| Aldo Paolicchi | |||
| Giorgio Iervasi | |||
| Monica Bocchia | |||
| Sabino Scolletta | |||
| Alessandro Gozzetti | |||
| Bruno Frediani | |||
| Federico Franchi | |||
| Federico Simonetti | |||
| Daniela Nasso | |||
| Annarosa Cuccaro | |||
| Ilaria Bertaggia | |||
| Edoardo Conticini | |||
| Paolo Roncucci | |||
| Spartaco Sani | |||
| Davide Carrara | |||
| Rossella Riccioni | |||
| Enrico Capochiani | |||
| P2860 | cites work | Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms | Q34021151 |
| Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology | Q39279748 | ||
| Reactive hemophagocytic syndrome in adults: a retrospective analysis of 162 patients. | Q40206962 | ||
| Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study | Q40557821 | ||
| Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China | Q83767469 | ||
| A pneumonia outbreak associated with a new coronavirus of probable bat origin | Q84367633 | ||
| Pathological findings of COVID-19 associated with acute respiratory distress syndrome | Q87281430 | ||
| Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study | Q87412594 | ||
| Overlapping and discrete aspects of the pathology and pathogenesis of the emerging human pathogenic coronaviruses SARS-CoV, MERS-CoV, and 2019-nCoV | Q87461558 | ||
| Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease | Q87635679 | ||
| Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China | Q87759574 | ||
| Viral load of SARS-CoV-2 in clinical samples | Q87843131 | ||
| COVID-19: combining antiviral and anti-inflammatory treatments | Q87865652 | ||
| FDA Approval Summary: Ruxolitinib for Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease | Q89647000 | ||
| Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial | Q90181685 | ||
| Histopathologic Changes and SARS-CoV-2 Immunostaining in the Lung of a Patient With COVID-19 | Q90263766 | ||
| Findings of lung ultrasonography of novel corona virus pneumonia during the 2019-2020 epidemic | Q90286894 | ||
| COVID-19: consider cytokine storm syndromes and immunosuppression | Q90464964 | ||
| Surviving Sepsis Campaign: Guidelines on the Management of Critically Ill Adults with Coronavirus Disease 2019 (COVID-19) | Q90735399 | ||
| Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy | Q91588064 | ||
| Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations | Q91766310 | ||
| Covid-19 in Immune-Mediated Inflammatory Diseases - Case Series from New York | Q94458250 | ||
| The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation | Q96230236 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P921 | main subject | acute respiratory distress syndrome | Q344873 |
| data collection | Q4929239 | ||
| ruxolitinib | Q7383611 | ||
| COVID-19 | Q84263196 | ||
| COVID-19-related data | Q107129120 | ||
| P304 | page(s) | 466 | |
| P577 | publication date | 2020-08-04 | |
| P1433 | published in | Frontiers in Medicine | Q27726181 |
| P1476 | title | Ruxolitinib Rapidly Reduces Acute Respiratory Distress Syndrome in COVID-19 Disease. Analysis of Data Collection From RESPIRE Protocol | |
| P478 | volume | 7 |
| Q103009676 | JAK-STAT pathway inhibition and their implications in COVID-19 therapy | cites work | P2860 |
Search more.